NCT05237453 (PUMA) is a NA clinical trial of Photons in Non-small Cell Lung Cancer, sponsored by University Hospital Heidelberg.

Who is sponsoring NCT05237453?

NCT05237453 is sponsored by University Hospital Heidelberg.

What drugs are being tested in NCT05237453?

Interventions in NCT05237453: Photons.

What condition does NCT05237453 study?

NCT05237453 studies Non-small Cell Lung Cancer.

Is NCT05237453 still recruiting?

NCT05237453 is currently active, enrolled. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT05237453: PUMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary Magnetic Resonance-guided Online Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer

Active, enrolled NA Last updated 9 March 2026

What this trial tests

NA trial testing Photons in Non-small Cell Lung Cancer in 30 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 June 2022

Primary endpoint
1 March 2027

1 March 2028

Quick facts

Lead sponsor	University Hospital Heidelberg
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	23 June 2022
Primary completion	1 March 2027
Estimated completion	1 March 2028
Sites	3 locations across Germany

Drugs / interventions tested

Photons

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

University Hospital Heidelberg

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MR-guided radiotherapy is an innovative technique which supports sophisticated approaches towards pulmonary adaptive radiotherapy (ART). Such individualized treatment approaches can lead to reduced toxicity and potentially better local tumor control for patients with LA-NSCLC in the future. PUMA is an early clinical trial, which aims to demonstrate the feasibility of MR-guided online ART to locally-advanced NSCLC. In a second step, the investigators aim to use the data from this feasibility trial to design and launch a further phase I/II clinical study that directly compares the benefits of MR-guided online ART of LA-NSCLC to CT-based (A)RT approaches.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.
Kong FS, Hu C, Pryma DA, Duan F, et al · · 2024 · cited 21× · PMID 39365957 · DOI 10.1200/jco.24.00022
Pulmonary magnetic resonance-guided online adaptive radiotherapy of locally advanced: the PUMA trial.
Regnery S, de Colle C, Eze C, Corradini S, et al · · 2023 · cited 11× · PMID 37143154 · DOI 10.1186/s13014-023-02258-9
The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours.
Hering S, Nieto A, Marschner S, Hofmaier J, et al · · 2024 · cited 6× · PMID 38433949 · DOI 10.1016/j.ctro.2024.100736
Harnessing the Power of Radiotherapy for Lung Cancer: A Narrative Review of the Evolving Role of Magnetic Resonance Imaging Guidance.
Cheng SH, Lee SY, Lee HH. · · 2024 · cited 3× · PMID 39123438 · DOI 10.3390/cancers16152710
Key technologies and challenges in online adaptive radiotherapy for lung cancer.
Dong B, Zheng S, Chen K, Zhu X, et al · · 2025 · cited 2× · PMID 39307926 · DOI 10.1097/cm9.0000000000003299

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other University Hospital Heidelberg trials

Trials by the same sponsor.

NCT07388147 — Exercise Therapy for Multiple Myeloma Patients · NA · not yet recruiting
NCT07348874 — Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany · not yet recruiting
NCT07181928 — Is Mentalization-based Therapy More Effective Than Treatment-as-usual for Adolescents With Dissocial Disorders? · NA · not yet recruiting
NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05237453 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Heidelberg
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05237453.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing